Ibrado A M, Kim C N, Bhalla K
Department of Medicine, Winship Cancer Center Emory University School of Medicine, Atlanta, GA 30322, USA.
Leukemia. 1998 Dec;12(12):1930-6. doi: 10.1038/sj.leu.2401218.
The antimicrotubule anticancer drug, Taxol, suppresses microtubule dynamics, causes mitotic arrest, and induces caspase-3 cleavage and activity resulting in apoptosis of human AML HL-60 cells. Caspase-3 cleavage is triggered by the mitochondrial release and cytosolic accumulation of the electron transfer protein, cytochrome c (cyt c). Taxol-induced G2/M transition is mediated by p34(cdc-2) (CDK1) which, if prematurely activated, may also trigger apoptosis. In the present studies following S-phase synchronization and release, HL-60 cells with enforced expression of the bcl-xL (HL-60/Bcl-xL) and/or neomycin resistance gene (HL-60/neo) were exposed to Taxol to examine CDK1-related cell-cycle events and the cyt c-triggered molecular cascade of apoptosis. At various time-intervals after Taxol treatment, immunoblot analyses of cyclin B1 and CDK1 levels were performed. In addition, the in vitro histone H1 kinase activity of immunoprecipitated CDK1 and its tyrosine phosphorylation status (by anti-phosphotyrosine immunoblot analysis) were determined. Data presented here show that, while Taxol-induced peak CDK1 kinase activity occurs earlier in HL-60/neo cells, there are no significant differences in cyclin B1 accumulation, tyrosine dephosphorylation of CDK1, and mitotic arrest of Taxol-treated HL-60/neo vs HL-60/Bcl-xL cells. Taxol-induced CDK1 activation and mitosis preceded the cytosolic accumulation (approximately six-fold) of cyt c. The latter event was blocked by Bcl-xL overexpression but not by inhibitors of caspase-3. Although the caspase inhibitors and high Bcl-xL levels inhibited caspase-3 cleavage and activity, they did not significantly affect Taxol-induced CDK1 activation or mitotic arrest. These findings indicate that Bcl-xL overexpression does not affect Taxol-induced CDK1 activity leading to G2/M transition, which temporally precedes the cytosolic cyt c-mediated cleavage and activity of caspase-3 and apoptosis.
抗微管抗癌药物紫杉醇可抑制微管动力学,导致有丝分裂停滞,并诱导半胱天冬酶-3的切割和活性,从而导致人急性髓系白血病HL-60细胞凋亡。半胱天冬酶-3的切割是由电子传递蛋白细胞色素c(cyt c)的线粒体释放和胞质积累触发的。紫杉醇诱导的G2/M期转换由p34(cdc-2)(CDK1)介导,若其过早激活,也可能触发凋亡。在本研究中,经S期同步化和释放后,强制表达bcl-xL(HL-60/Bcl-xL)和/或新霉素抗性基因(HL-60/neo)的HL-60细胞暴露于紫杉醇,以检查与CDK1相关的细胞周期事件以及cyt c触发的凋亡分子级联反应。在紫杉醇处理后的不同时间间隔,进行细胞周期蛋白B1和CDK1水平的免疫印迹分析。此外,还测定了免疫沉淀的CDK1的体外组蛋白H1激酶活性及其酪氨酸磷酸化状态(通过抗磷酸酪氨酸免疫印迹分析)。此处呈现的数据表明,虽然紫杉醇诱导的CDK1激酶活性峰值在HL-60/neo细胞中出现得更早,但在细胞周期蛋白B1积累、CDK1的酪氨酸去磷酸化以及紫杉醇处理的HL-60/neo细胞与HL-60/Bcl-xL细胞的有丝分裂停滞方面并无显著差异。紫杉醇诱导的CDK1激活和有丝分裂先于cyt c的胞质积累(约六倍)。后一事件被Bcl-xL的过表达所阻断,但未被半胱天冬酶-3抑制剂阻断。尽管半胱天冬酶抑制剂和高Bcl-xL水平抑制了半胱天冬酶-3的切割和活性,但它们并未显著影响紫杉醇诱导的CDK1激活或有丝分裂停滞。这些发现表明,Bcl-xL的过表达并不影响紫杉醇诱导的导致G2/M期转换的CDK1活性,而G2/M期转换在时间上先于胞质cyt c介导的半胱天冬酶-3的切割和活性以及凋亡。